References
1.
O’Shaughnessy J. Emergency use authorization
091. Published online 2022. https://www.fda.gov/media/145610/download
2.
Weinrich D, Sivapalasingam S, Norton T, Ali S,
Bhore R. REGN-COV2, a neutralizing antibody cocktail, in outpatients
with covid-19. N Engl J Med. 2021;384(3):238-251. doi:10.1056/NEJMoa2035002
3.
O’Shaughnessy J. Emergency use authorization
094. Published online 2022. https://www.fda.gov/media/145801/download
4.
Dougan M, Azizad M, B BM, Gottlieb R. A
randomized, placebo-controlled clinical trial of bamlanivimab and
etesevimab together in high-risk ambulatory patients with COVID-19 and
validation of the prognostic value of persistently high viral load.
Clin Infect Dis. 2022;75(1). doi:10.1093/cid/ciab912
5.
O’Shaughnessy J. Emergency use authorization
100. Published online 2022. https://www.fda.gov/media/149532/download
6.
Gupta A, Y YGR, Juarez E. Effect of sotrovimab
on hospitalization or death among high-risk patients with mild to
moderate COVID-19: A randomized clinical trial. JAMA.
2022;327(13). doi:10.1001/jama.2022.2832
7.
O’Shaughnessy J. Emergency use authorization
111. Published online 2022. https://www.fda.gov/media/156151/download
8.
Lilly E et al. A study of immune system
proteins in participants with mild to moderate COVID-19 illness.
Published online 2020. https://clinicaltrials.gov/study/NCT04634409
9.
Bariola JR, McCreary EK, Wadas RJ, et al.
Impact of bamlanivimab monoclonal antibody treatment on hospitalization
and mortality among nonhospitalized adults with severe acute respiratory
syndrome coronavirus 2 infection. In: Open Forum Infectious
Diseases. Vol 8. Oxford University Press US; 2021:ofab254.
10.
Ganesh R, Pawlowski CF, O’Horo JC, et al.
Intravenous bamlanivimab use associates with reduced hospitalization in
high-risk patients with mild to moderate COVID-19. The Journal of
clinical investigation. 2021;131(19).
11.
Iqbal L, Terlau TJ, Hernandez A, Woods K,
Terlau T, Hernandez AT. Efficacy of bamlanivimab in reducing
hospitalization and mortality rates in COVID-19 patients in a rural
community. Cureus. 2021;13(7).
12.
Melton III JD, Wilson K, Blind F, et al. Impact
of early versus late administration of bamlanivimab on readmissions in
patients with high-risk COVID-19. The American Journal of Emergency
Medicine. 2021;50:437-441.
13.
Aggarwal NR, Beaty LE, Bennett TD, et al.
Real-world evidence of the neutralizing monoclonal antibody sotrovimab
for preventing hospitalization and mortality in COVID-19 outpatients.
The Journal of Infectious Diseases.
2022;226(12):2129-2136.
14.
Cheng MM, Reyes C, Satram S, et al. Real-world
effectiveness of sotrovimab for the early treatment of COVID-19 during
SARS-CoV-2 delta and omicron waves in the USA. Infectious Diseases
and Therapy. 2023;12(2):607-621.
15.
Molina KC, Kennerley V, Beaty LE, et al.
Real-world evaluation of bebtelovimab effectiveness during the period of
COVID-19 omicron variants, including BA. 4/BA. 5. International
Journal of Infectious Diseases. 2023;132:34-39.
16.
Sridhara S, Gungor AB, Erol HK, et al. Lack of
effectiveness of bebtelovimab monoclonal antibody among high-risk
patients with SARS-cov-2 omicron during BA. 2, BA. 2.12. 1 and BA. 5
subvariants dominated era. Plos one. 2023;18(4):e0279326.
17.
Wynia MK, Beaty LE, Bennett TD, et al.
Real-world evidence of neutralizing monoclonal antibodies for preventing
hospitalization and mortality in COVID-19 outpatients. Chest.
2023;163(5):1061-1070.
18.
Kip
KE, McCreary EK, Collins K, et al. Evolving real-world effectiveness of
monoclonal antibodies for treatment of COVID-19: A cohort study.
Annals of Internal Medicine. 2023;176(4):496-504.
19.
RStudio Team. RStudio: Integrated
Development Environment for r. RStudio, PBC; 2022. http://www.rstudio.com/
20.
Ho
DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric
preprocessing for parametric causal inference. Journal of
Statistical Software. 2011;42:1-28. doi:10.18637/jss.v042.i08